Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
2(13%)
Results Posted
67%(4 trials)
Terminated
3(19%)

Phase Distribution

Ph phase_1
3
19%
Ph phase_2
2
13%
Ph not_applicable
4
25%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
2(22.2%)
N/ANon-phased studies
4(44.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

2

trials recruiting

Total Trials

16

all time

Status Distribution
Active(2)
Completed(6)
Terminated(3)
Other(5)

Detailed Status

Completed6
unknown5
Terminated3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
16
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (33.3%)
Phase 22 (22.2%)
N/A4 (44.4%)

Trials by Status

completed638%
unknown531%
recruiting213%
terminated319%

Recent Activity

2 active trials
Showing 5 of 16
recruitingphase_2

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

NCT07062055
recruiting

Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC

NCT06537908
terminatedphase_1

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

NCT04171141
completedphase_1

CLN-0046: Treatment of AMD Subjects With OTX-TKI

NCT03630315
completed

Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors

NCT06119347
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT07062055Phase 2

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Recruiting
NCT06537908

Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC

Recruiting
NCT04171141Phase 1

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Terminated
NCT03630315Phase 1

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Completed
NCT06119347

Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors

Completed
NCT04626128Phase 1

Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

Completed
NCT05156021Not Applicable

A Study on the Treatment Strategy of NVG Secondary to PDR

Completed
NCT05759884Not Applicable

Efficacy Analysis of Anti-VEGF Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema

Unknown
NCT05678517

Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD

Completed
NCT02348359Phase 2

X-82 to Treat Age-related Macular Degeneration

Terminated
NCT04962438

Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function

Unknown
NCT03699618

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Terminated
NCT01918371

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

Completed
NCT03762226

Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study

Unknown
NCT03633266Not Applicable

Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy

Unknown
NCT03637283Not Applicable

Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage

Unknown

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16